Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 8,90 € (-64,23 %). Medianen er 8,90 € (-64,23 %).
| Køb |
11 |
| Behold |
8 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Mersana Therapeutics releases quarterly results for Sept. 30, 2025 – analysts expect smaller loss per share
Mersana Therapeutics will publish results for the quarter ended Sept. 30, 2025 on Nov. 14, 2025. Eight analysts on average expect earnings per share of -$1.544, an improvement of 31.38% from the year-ago quarter (-$2.250). Nine analysts estimate quarterly revenue at an average of $14.2 million (up 12.7% from $12.6 million). For the current fiscal year analysts expect on average a loss of -$6.784 per share and revenue of around $25.3 million (prior year: $40.5 million). » Mere på finanzen.net
Virksomhedstal
| (EUR) | september 2025 | YoY |
|---|---|---|
| Omsætning | 9,38 mio. | - |
| Bruttofortjeneste | 9,38 mio. | - |
| Nettoresultat | -6,43 mio. | - |
| EBITDA | -6,02 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 129,31 mio. € |
Antal aktier | 5 mio. |
Højeste/laveste i 52 uger | 27,03 € - 4,63 € |
| Udbytte | Nej |
Beta | 0,43 |
P/E (PE Ratio) | -4,56 |
PEG (PEG Ratio) | -0,62 |
K/I (PB Ratio) | -2,44 |
P/S (PS Ratio) | 10,34 |
Virksomhedsprofil
| Navn | Mersana Therapeutics Inc |
| CEO | Martin H. Huber |
| Medarbejdere | 102 |
